In FY13, Piramal Enterprises sold its domestic pharmaceutical formulations business to Abbott Laboratories for ₹17,000 crore and had invested part of the proceeds in Shriram Group companies. Piramal invested ₹4,583 crore across three Shriram Group entities, according to a Crisil report.